Abstract:Background: The interaction of multiple myeloma (MM) cells with macrophages (MΦs) in the bone marrow microenvironment contributes to the pathophysiology of MM. In addition to promoting angiogenesis through vasculogenic mimicry, MM-associated MΦs (mMΦs) protect MM cells from spontaneous and chemotherapy-induced apoptosis. mMΦs therefore represent a potential target for myeloma treatment and it is essential to explore the mechanisms underlying normal MΦ polarization to mMΦs. We previously showed that IL-32 is overexpressed in MM patients and is mainly derived from MM cells. The present study was designed to explore the clinical significance of IL-32 in MM and to further elucidate the molecular mechanisms underlying the IL-32-mediated immune function of MΦs. Methods: We examined the expression of IL-32 in bone marrow biopsy samples using immunohistochemistry. Quantitative real-time PCR, western blot analysis and immunofluorescence were applied to measure the expression of IL-32, IDO and proteinase 3 (PR3). We obtained the global transcriptional profile of the IL-32γ-treated MΦs by RNA sequencing (RNA-Seq). Immunoprecipitation (IP) and GST pulldown experiments was applied to confirm the binding affinity of PR3 for IL-32. We created IL-32-knockdown MM cells by transfection of IL-32 shRNA and silenced PR3 expression in MΦs using siRNA targeting PR3. CD4+ T cell proliferation and IL-2, IFN-γ and TNF-α production were measured by flow cytometry. Results: We found that high IL-32 expression in MM patients was associated with advanced clinical stage and high serum β2-microglobulin levels. Several isoforms of IL-32 were detected in MM cells and IL-32γ was the most active subtype. RNA sequencing revealed that IL-32γ significantly induced the production of the immunosuppressive molecule indoleamine 2,3-dioxygenase (IDO) in MΦs and this effect was verified at the protein level. Furthermore, IL-32-knockdown MM cells showed less ability than control MM cells to promote IDO expression. As a binding protein for IL-32, PR3 was universally expressed on the surface of MΦs and knockdown of PR3 or inhibition of the STAT3 and nuclear factor κB (NF-κB) pathways hindered the IL-32γ-mediated stimulation of IDO expression. Finally, IDO-positive IL-32γ-educated MΦs inhibited CD4+ T cell proliferation and IL-2, IFN-γ and TNF-α production in response to activation. Conclusion: Our study showed that MM cell-derived IL-32γ induced IDO production in MΦs through PR3 and the downstream STAT3 and NF-κB pathways, resulting in the suppression of the proliferation and effector function of CD4+ T cells. High IL-32 expression in MM may contribute to an immunosuppressive microenvironment by upregulating IDO production in MΦs and promote MM progression. Disclosures No relevant conflicts of interest to declare.

Two-dimensional SU(N) x SU(N) chiral models on the lattice.

Interleukin-32 Alpha Promotes The Proliferation Of Multiple Myeloma Cells By Inducing Production Of Il-6 In Bone Marrow Stromal Cells

IL-10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in multiple myeloma

YL064 Directly Inhibits STAT3 Activity to Induce Apoptosis of Multiple Myeloma Cells

Abnormal repression of SHP-1, SHP-2 and SOCS-1 transcription sustains the activation of the JAK/STAT3 pathway and the progression of the disease in multiple myeloma

HMGB1 Knockdown Increases MM Cell Vulnerability by Regulating Autophagy and DNA Damage Repair

CAMKIIγ is a Targetable Driver of Multiple Myeloma Through CaMKIIγ/ Stat3 Axis

Polyphyllin I Induces Cell Cycle Arrest and Apoptosis in Human Myeloma Cells Via Modulating Β‐catenin Signaling Pathway

Il-32 Gamma Induces M2 Macrophage Polarization With Enhanced Ability Of Macrophage-Mediated Drug Resistance In Myeloma Cells Through Stat3 And Ne-Kappa B Activation

CXCL10 recruitment of γδ T cells into the hypoxic bone marrow environment leads to IL-17 expression and multiple myeloma progression

IL-32γ Induces M2 Macrophage Polarization with Enhanced Ability of Macrophage-Mediated Drug Resistance in Myeloma Cells through STAT3 and NF-κB Activation

Multiple Myeloma Cell-Derived Interleukin-32gamma Increases the Immunosuppressive Function of Macrophages by Promoting Indoleamine 2,3-Dioxygenase (IDO) Expression

Acute accumulation of PIM2 and NRF2 and recovery of β5 subunit activity mitigate multiple myeloma cell susceptibility to proteasome inhibitors

IL-6 Inhibits Apoptosis of Human Myeloma Cell Line XG-7 Through Activation of JAK/STAT Pathway and Up-Regulation of Mcl-1.

Significant Biological Role of Sp1 Transactivation in Multiple Myeloma

Pgc1 Beta Regulates Multiple Myeloma Tumor Growth Through Ldha-Mediated Glycolytic Metabolism

Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity

LILRB4 regulates multiple myeloma development through STAT3-PFKFB1 pathway

Stat3 Exerts Two-Way Regulation In The Biological Effects Of Il-6 In M1 Leukemia Cells

A Novel Small Molecule Agent Displays Potent Anti-Myeloma Activity by Inhibiting the JAK2-STAT3 Signaling Pathway.

Ribosomal protein S3 mediates drug resistance of proteasome inhibitor: potential therapeutic application in multiple myeloma